In 2019, a tetraplegic French patient walked on an exoskeleton powered by a brain implant. In 2023, a Dutch man named Gert-Jan Oskam walked again after the same implant was paired with a spinal stimulator. On 3 June 2026, the French national research institute behind that implant said it has applied for regulatory authorization to take the same brain-computer interface platform into a much larger patient population: people recovering from stroke. CEA-Leti, the applied research arm of France’s Alternative Energies and Atomic Energy Commission (CEA), announced the BCI4Stroke clinical trial as part of the broader BrainSync project under France’s €40 million Audace! programme. The trial is registered on ClinicalTrials.gov as NCT07477613, with first patient enrolment expected in 2026.

The platform being extended

BCI4Stroke uses the WIMAGINE® implant, an epidural (between skull and cortex) wireless brain-recording device developed at CEA Clinatec in Grenoble. The platform has been the engine behind two of the most-cited results in implantable BCI history. The 2019 demonstration (Benabid et al., The Lancet Neurology) implanted a tetraplegic patient with bilateral WIMAGINE arrays and showed thought-driven control of a four-limb exoskeleton. The 2023 demonstration (Lorach et al., Nature) paired WIMAGINE with the Courtine and Bloch spinal stimulator architecture and restored natural walking to Gert-Jan Oskam, in the “digital bridge” result that became the foundational clinical reference for the brain-spine interface category that ONWARD Medical’s ARC-BCI now commercialises.

The structural shift in BCI4Stroke is the patient population. WIMAGINE’s prior public-domain demonstrations have been single-digit-patient proof points in spinal cord injury and severe motor impairment, which collectively address a relatively small global addressable population. Stroke is roughly 150,000 patients per year in France alone and tens of millions globally, with motor impairment as one of the most common long-term sequelae. Extending the platform into post-stroke rehabilitation moves WIMAGINE from a category-defining proof-of-concept platform to a candidate for the much larger neurorehabilitation market.

What BCI4Stroke is testing

The clinical protocol couples the WIMAGINE implant with decoding software that captures and predicts a patient’s movement intentions, then routes those intentions to one of three rehabilitation tools: a robotic glove, a surface stimulator, or a virtual-environment interface. The premise is that real-time pairing of detected motor intention with sensorimotor feedback drives neuroplasticity through repeated association, strengthening the neural pathways that mediate functional recovery. CEA-Leti describes the protocol as a six-month rehabilitation programme designed to evaluate whether the BCI-mediated pairing produces measurable gains in daily independence and reductions in residual disability beyond standard-of-care post-stroke rehabilitation.

The clinical sites named in the CEA-Leti announcement are Grenoble University Hospital and Saint-Étienne University Hospital, both in southeast France. The named clinical lead is Pr. Olivier Detante, neurologist at Grenoble Alpes University Hospital. The named technical leads at CEA-Leti are Serpil Karakas (software manager) and Lucas Struber (neurotechnology researcher).

How BCI4Stroke sits relative to the existing brain-spine cohort

The Lorach et al. 2023 brain-spine interface result is the clearest public-domain precedent for what CEA-Leti is now attempting in stroke. ONWARD Medical, the EPFL spinout commercialising the brain-spine architecture, reported in its Q1 2026 results that seven ARC-BCI participants have now been implanted. Grégoire Courtine and Jocelyne Bloch were named 2026 Queen Elizabeth Prize for Engineering co-laureates for the same brain-spine work alongside cochlear implant pioneers, deep brain stimulation pioneers, and BrainGate founder John Donoghue.

BCI4Stroke is not the same trial. It is the same WIMAGINE hardware platform applied to a different indication (stroke instead of spinal cord injury), with a different downstream actuation mechanism (rehabilitation tools rather than spinal cord stimulation), and a different mechanistic hypothesis (neuroplasticity-driven recovery rather than direct movement substitution). The shared platform across BCI4Stroke and the brain-spine programme is a structural signal that the WIMAGINE epidural-recording architecture is being treated as the European public-research neurotechnology platform of record, with multiple downstream clinical indications being layered on top.

The capital and policy stack underneath

The Audace! research programme was launched by CEA in March 2025 at the request of the French government, with €40 million of funding under France 2030. The programme is structured around approximately ten projects across CEA research fields, with over 80 academic partners across France. BrainSync is the brain-computer interface project within Audace!. CEA-Leti’s BCI4Stroke work is additionally supported by a European Innovation Council (EIC) grant under the Horizon Europe programme.

This is the same European public-capital-meets-public-research pattern Inside BCI has been threading across multiple recent pieces, including INBRAIN Neuroelectronics in Barcelona (Spanish CDTI-Innvierte and Catalan public capital), ABILITY Neurotech in Geneva (Wyss Center incubation), and Neurosoft Bioelectronics (EIF-anchored Skybound seed). The CEA-Leti BCI4Stroke programme adds France’s national applied research apparatus to that pattern in the post-stroke indication, with the country’s tier-one neurology hospitals as the clinical sites.

What to watch

The first signal is the regulatory authorization date and the first-patient implantation date. CEA-Leti has applied for authorization but not yet received it; the announcement frames first patient enrolment as “expected in 2026” without committing to a specific quarter. The second signal is whether the six-month rehabilitation protocol produces measurable functional outcomes that are publishable in a tier-one neurology or rehabilitation journal. The 2019 and 2023 WIMAGINE results were published in The Lancet Neurology and Nature respectively; the BCI4Stroke readout will be benchmarked against that publication standard. The third signal is whether the BCI4Stroke approach scales to a broader European clinical network beyond the initial two Grenoble and Saint-Étienne sites, which would convert the trial from a single-country proof of concept into a pan-European stroke-rehabilitation platform.

Sources

• Brain-Computer Interface: A New Era for Post-Stroke Rehabilitation (CEA-Leti, 3 June 2026)
• BCI4Stroke clinical trial registration (ClinicalTrials.gov NCT07477613)
• Lorach H. et al., Walking naturally after spinal cord injury using a brain-spine interface (Nature 618.7963 (2023): 126-133)
• Benabid A.L. et al., An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration (The Lancet Neurology 18.12 (2019): 1112-1122)
• BrainSync project (CEA Audace! programme overview)